Section Head, Rare Genetics and Hematology, Quantitative Clinical PharmacologyTakeda Development Center Americas, Inc., Cambridge, MA, USACambridge, Massachusetts, United States
OC 14.2 - Pharmacokinetic characteristics of ADAMTS13 in patients with congenital thrombotic thrombocytopenic purpura: Interim results from a phase 3 randomized, controlled, open-label, crossover study
Sunday, June 25, 202311:00 – 11:15 ET
